Sajjadi, Elham
Venetis, Konstantinos
Piciotti, Roberto
Invernizzi, Marco
Guerini-Rocco, Elena
Haricharan, Svasti
Fusco, Nicola http://orcid.org/0000-0002-9101-9131
Article History
Received: 5 March 2021
Accepted: 7 May 2021
First Online: 17 May 2021
Declarations
:
: Not applicable.
: Not applicable.
: M.I. received honoraria for consulting/advisory role/speaker bureau from Errekappa Euroterapici S.p.a. E.G.R. has received advisory fees from Novartis, Roche, and MSD Italia; honoraria from Thermo Fisher Scientific, AstraZeneca, Roche. S.H. has two provisional patent licenses outlining a role for DNA repair defects in predicting response to therapies in breast cancer patients (Serial Nos: 62/670,368, 63/106777). N.F. has received honoraria for consulting, advisory role, and/or speaker bureau from Merck Sharp & Dohme (MSD), Boehringer Ingelheim, and Novartis. These companies had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and/or in the decision to publish the results. All other authors declare that they have no competing interests.